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ATYPICAL CASE OF 
SYNCOPE AS A CHEST 
PAIN EQUIVALENT IN 
PATIENT WITH ACUTE 
MYOCARDIAL 
INFARCTION  
• Syncope may be the initial complaint in 5-12% of patients with acute myocardial 
infarction (MI) and is related to arrhythmia or pump failure.  
• Vasovagal reactions, bradyarrhythmia and atrioventricular blocks can be caused by 
ischemia. 
•  Patients suffering from acute mi are susceptible to neurally mediated syncopal or 
presyncopal attacks.  
• Sympathetic withdrawal seems to be one of the most likely mechanism of syncope in 
patients with acute mi.  
 
In the general population, frequent premature ventricular contractions (PVCs), which 
are defined as the presence of at least 1 PVC on a 12-lead ECG or >30 PVCs per hour, 
are associated with increased cardiovascular risk and increased mortality. 
PVC and  nonsustained ventricular tachycardia (NSVT) in patients with cardiovascular 
disease are common and have been associated with adverse outcomes. 
 
 
INTRO 
OUR PATIENT 
► Patient M 
► 80 year old  
► Scientist 
►City resident 
COMPLAINTS 
► Was hospitalized 15/01/2019 with 
complains of: 
► Pressing chest pain with irradiation 
to the  left shoulder  after 
moderate physical activity  
► Chest pain was relieved by taking 
nitroglycerin 
► Dyspnea 
► Pitting edemas  
► Deterioration over 2 month 
ANAMNESIS MORBI 
► In 2005 suffered – acute Q-positive posterior-diaphragmal MI and acute 
anterior-septal MI- in 2006. In both cases during daily routine activity the onset 
of acute cardiovascular event was presented only by syncope episode.  
► Ischemic heart disease since 2001 
► First experience of retrosternal pains in 2006 
► Blood pressure levels usual are 130/70, max-170/100 
► Hypertensive retinal angiopathy since 2005 
► Dyscirculatory encephalopathy of 2nd degree since 2010 
 
ANAMNESIS VITAE  
►Non diabetic 
►  No history head trauma or epilepsy 
►Hereditary diseases were not identified 
►Allergic history is not burdened 
► Sexually transmitted diseases were denied 
►CV disease family history: absent 
►Chronic bilateral hearing loss  since 2010 
►Chronic non-calculous cholecytopancreatitis 
 
OBJECTIVE STATUS 
 
 
 Consciousness - clear, state – moderate severe, body position – active  
 Patient can orient himself in place, time, his personality 
 Weight -90 kg, height- 167 cm, waist circumference-105, BMI- 33 
 Pale skin and mucosae; Musculoskeletal system – no changes 
 BR (breathing rate) – 18 /min 
 Lung percussion: no clinically significant changes 
 Lung auscultation: Vesicular breathing weakened in the lower parts  
 Heart borders: right - right edge of the sternum; left - 1.5 cm left of middle 
clavicle line; upper - in  3rd  intercostal space 
 Heart auscultation: arrhythmic, extrasystoles 2-3 in min, heart tones –deaf,  
 Pulse – arrhythmic, 60 bpm; Blood pressure (BP) 110/80 mm Hg (over background of 
antihypertensive therapy) 
 Abdomen - enlarged, symmetric, unpainful;  Edemas - moderate  
 Liver: + 1.5-2 cm, no pain during palpation of right hypochondrium; Spleen: normal 
 Pasternatsky symptom – negative from both sides 
 
 
• 15 .01 .19  ECG revea led s inus  rhythm, hear t  rate  60  in  min , the e lectr ica l  ax is  of  the hear t  i s  
de f lected to the le f t ,  ventr icu lar  premature contract ion , repolar izat ion  abnormal i t ies  in  V4 -V6 .  
24HR-ECG MONITORING 
• During observation displacement of ST segment not detected.  
• Circadian oscillations persist - a tendency to slow down the 
rhythm 
• Bradycardia at night - up to 40 per minute 
• Up to 30 pauses 1700 ms/day, mainly at night 
•  Signs of AV blockade is not revealed 
 
Rhythm disturbances:  
•Supraventricular extrasystoles up to 31 per hour 
• Short-term allorhythmias such as bigeminies, couplets rare,  
•Triplet on 01/17/19 (during activity) 
•Ventricular extrasystoles - 31 per hour, predominantly single, 
short-term allorhythmias of the bigeminy type, monomorphic, 
group and early extrasystoles were not detected - grade 1 by 
Laun. 
COMPLETE 
BLOOD 
COUNT 
Conclusion: no clinically 
important changes 
15/01/19 Normal Range 
Hemoglobin, g/l  142 130 – 160 
Red blood cells, 
1012 
4.63 4.0 – 5.0  
Ht 46 40-48% 
White blood cells, 
109 
7.8 4 - 9 
ESR, mm/h 7 1 -10 
Bands  2 1.06 – 6% 
Segments  68 47 – 72% 
Eosinophils  3 0.5 – 5% 
Monocytes  2 0.1 – 3% 
Lymphocytes  25 19 – 37 % 
Platelets  263 180-320 
  BIOCHEMISTRY TEST DATA  
 
Patient’s ranges, N 
Glucose (mmol/l) 3.8 3.38 – 5.55 
Total bilirubin, mkmol/l 17.7 8.6 – 25.5 
AST, μmol/h*ml 0.2 0.1-0.445 
ALT, U/l 0.4 0.1-0.68 
Prothrombin index (%) 87% 85-105 
Creatinine, μmol/l 84 80 – 115 
K (mmol/l) 4.2 3.5-5.1 
Ca (mmol/l) 2.13 2.15—2.50 
Na (mmol/l) 136 135-145 
СL (mmol/l) 100 98—107 
C-reactive protein negative 
Total cholesterol  3.3 < 6.2 
Conclusion: no clinically important changes 
 
HEART ULTRASOUND 
During an heart ultrasound was found  
► Hypokinesia of left ventricle posterior wall  
► Global contractility decline with EF -44% 
► Dilation of left atrium 
 
No pulmonary hypertension,  
► Atherosclerotic changes of aorta present 
 
No ventricular septal defect or mitral valve 
significant changes were noted. 
COMPLETE DIAGNOSIS 
 
 
► Main: Ischemic Heart Disease:- stable angina III functional class, postinfarction (2005, 
2006 – Q-positive) and diffuse  cardiosclerosis. 
•  Aortic sclerosis .  Arterial Hypertension III degree, 2 stage, very high risk. 
• Extrasystolic arrhythmia  grade 1 by Laun.  
 
► Complications: Chronic Heart Failure IIB stage with left ventricle systolic 
dysfunction (EF – 44%) 
 
►  Concomitant diseases: 
•  Dyscirculatory encephalopathy of 2nd degree  
•  Chronic bilateral hearing loss, hypertensive retinal angiopathy 
• Chronic non-calculous cholecystopancreatitis 
 
GENERAL PRINCIPLES OF 
TREATMENT OF SYNCOPE 
 
 General framework of treatment is 
based on risk stratification and the 
identification of specific mechanisms 
when possible. 
 
 In our clinical case - it is impossible to 
establish the real cause of the syncope.  
 Since the changes in the available ECG 
reduce the structural changes in the 
myocardium, which occurred due to 
two myocardial infarctions. 
 And this patient can be associated with 
a high risk of sudden death 
 
 
 
 ARVC = arrhythmogenic right ventricular cardiomyopathy; CAD = coronary artery disease; DCM = dilated cardiomyopathy; ECG = electrocardiographic; HCM = hypertrophic 
cardiomyopathy; ICD = implantable cardioverter defibrillator; LQTS = long QT syndrome; SCD = sudden cardiac death. 
https://academic.oup.com/eurheartj/article/39/21/1883/4939241#119215785 
FOR PREVENTION OF FURTHER SUDDEN CARDIAC DEATH 
PT SHOULD BE RECOMMENDED 
► For secondary prevention, individuals aged 75 years with clinical atherosclerotic cardiovascular disease (ASCVD) should be started 
on high-intensity statin therapy unless contraindicated 
The goals 
► BP <140/90 mm Hg in all patients - initiate or maintain lifestyle modification, weight control, increased physical activity, alcohol 
moderation, sodium reduction, and increased consumption of fresh fruits, vegetables, and low-fat dairy products. 
► achieving low-density lipoprotein cholesterol (LDL-C) levels below 100 mg/dL; if triglyceride levels are 200 mg/dL or above, 
non-HDL-C (non-high-density lipoprotein cholesterol) levels should be below 130 mg/dL. (Non-HDL-C = total cholesterol – 
HDL-C.) 
Therapies  
► Initiate 12 month course of clopidogrel 75 mg/day in combination with aspirin in patients after acute coronary syndrome 
► Initiate indefinite course of beta-blockers in all patients who have had MI, ACS or LV dysfunction with or without heart failure 
symptoms, unless contraindicated. 
► Beta blockers reduce all-cause mortality and SCD in patients with HF with reduced EF and have long been proven to reduce 
mortality after MI 
►  Treatment of PVCs with antiarrhythmic medications has not been shown to reduce mortality and An electrophysiological study 
may be needed  
►   In patients with heart failure with reduced ejection fraction (HFrEF) (LVEF ≤40%) - treatment with a beta blocker, a 
mineralocorticoid receptor antagonist and either an ACE inhibitor, an angiotensin-receptor blocker, or an angiotensin receptor-
neprilysin inhibitor is recommended to reduce SCD and all-cause mortality 
 
https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000549 
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